

Asterion Cannabis Inc

11:30 20 Jul 2020

Asterion Cannabis updates on milestones in bid to become world's largest pharma-grade medicinal cannabis supplier

Asterion Cannabis Inc outlined the various significant milestones achieved as the private firm continues its bid to build the world's largest glasshouse medicinal cannabis production facility in Australia.

In a lengthy investor update, Asterion, which is currently raising C\$10 million via a placing, highlighted that in April last year, it inked a definitive deal to buy 75 acres of land in Toowoomba, adjacent to the Toowoomba Wellcamp Airport in Queensland.

READ: Asterion Cannabis launches C\$10M brokered private placement

The firm aims to construct a 4.3 million sq ft (40 hectares) facility, which will be built in three phases - the first and second phases being 10 hectares each.

It will include full extraction and processing equipment as well as a research and development (R&D) facility.

Asterion aims to have an initial product ready with revenues within 24 months of breaking ground, and has established strategic partnerships with various bodies, including the Australian Federal government, the University of Queensland and PreveCeutical Medical Inc (CSE:PREC) (OTCQB:PRVCF) .

With the latter, it has struck an option deal to buy up to 51% of PreveCeutical's right, title and interest in and to certain intellectual property (IP) rights relating to cannabinoid Sol-Gel -- a nose-to-brain delivery technology.

Last year, Asterion was also awarded 'Major Project Status' for the project by the Australian Federal Government, qualifying for a 'one-stop-shop' advantage to co-ordinate and expedite future approvals.

It is also applying for Australian import and export licenses to import cannabis products from Canada to supply to Australian patients.

As well as getting its medicinal cannabis licenses, Asterion entered into a Definitive Association Agreement for the development, engineering and construction services for Phase 1 of the project with Watpac Finance Pty Ltd and Watpac Construction Pty Ltd.

Watpac is also considering financing the first phase of the project (estimated at A\$400 million). Watpac is a wholly owned subsidiary of leading international construction company BESIX.

Under the terms of the financing, Asterion is offering nearly 6.7 million units at C\$1.50 each. Each unit consists of one share and one half of a share purchase warrant, with each warrant entitling the holder to buy a further share for C\$2 each for 24 months from closing.

Contact the author at giles@proactiveinvestors.com

Share Information

Code: AC
Listing: PRIVATE-CA
Sector: Cannabis
Website: asterioncannabis.com

Company Synopsis:

Asterion Cannabis Inc. is a Canadian medicinal cannabis company, with a wholly owned Australian subsidiary, Asterion (Australia) Pty Ltd. The company is focused on being a leader of advanced agriculture and producing the highest quality, low cost, genetically uniform strains of cannabis.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Asterion Cannabis Inc named herein, including the promotion by the Company of Asterion Cannabis Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).